Lecturers

ISOBM2022 Lecturers

(the list of lecturers is preliminary at the moment)


Lecturers

Lecturer Title of Lecture
Barak Vivian sIL-2R- an important Immuno- Biomarker for Cancer
Bendas Gerd Heparin in Oncology – Novel Targets and Activities for an Immuno-Oncological Perspective
Blatnik Ana Genetic analysis of archival tissue when testing for hederitary cancer predispositions
Boltežar Gašper The role of tumor markers in cystic lesions of the pancreas
Bombač Alenka Mutational spectrum in patients with metastatic gastrointestinal stromal tumours treated at Institute of Oncology Ljubljana
Bronkhorst Abel Jacobus Understanding biology of cell-free nucleic acids for clinical decision making
Chechlinska Magdalena Molecular profiling of ovarian tumor microenvironment
Colas Ortega Eva Use of biomarkers in diagnosis and presurgical patient stratification
Danesi Romano Clinical implementation of pharmacogenetics to reduce the risk of toxicity of anticancer drugs
Datar V New Dynamics in Cancer Outcomes: Encyclopaedic Tumour Analysis
Dragoš Štajerčič Vita The use of RNAseq in discovery of splicing abnormalities
Duffy Michael Personalised treatment for cancer: biomarkers are showing the way
Ecke Thorsten BTA stat, NMP22, UBC rapid test, UBC rapid visual, and uromonitor as tumour marker for urinary bladder cancer: interim results of a german multicentre-study
Ferrari Paola Inhibiting immunosuppression immunotherapy in solid tumors
Fishmann Dmytro Machine learning in medicine
Francesco Fanfani Implementing the TCGA classification endometrial cancer: consequences on medical and surgical approaches
Garrido Manuel Antonio Multi-biomarker evaluation in prostate cancer patients with PSA between 2 and 10 ng/mL
Haselmann Verena Implementation of liquid biopsy into patient care
Heitzer Ellen New developments in liquid biopsy diagnostics
Holdenrieder Stefan Current use of protein and molecular markers in guidance of lung cancer patients
Holdenrieder Stefan Proteomic and metabolomics multimarker approaches for lung cancer
Holdenrieder Stefan Nucleosomes and Exosomes as sources for biomarkers
Kagan Jakob Validation Studies of Biomarkers for Early Detection of Aggressive Prostate Cancer
Karlikova Marie Importance of Matrix metalloproteinases in tumour diseases
Kinkorova Judita Biobanking and big data
Kloft Charlote ONTARGET – TDM to optimize oral anticancer targeted therapy
Krajc Mateja Cancer genetic screening and personalised cancer risk assessment
Kučera Radek The importance of PHI for the prediction of surgical solution or active surveillance of prostate cancer patients
Lainšček Duško An enhanced CRISPR based tool for treating chronic myelogenous leukaemia
Lanišnik Rižner Tea AKR1C and AKR1B enzymes as biomarker candidates of endometrial and ovarian cancers
Lanišnik Rižner Tea BioEndoCar: Biomarkers for diagnosis and prognosis of endometrial carcinoma
Liszcova Libuše Genetic biomarkers in the diagnosis of diffuse gliomas
Looijenga Leendert Human germ cell tumours; clinical implementation of laboratory findings
Marc Janja Biomarkers in bone metastasis
Marta Sanchez-Carbayo Multiplexed -omics profiling for bladder Cancer diagnostics
Marta Sanchez-Carbayo Methylation profiles for bladder Cancer diagnostics
Marzia Del Re The application of liquid biopsy to cancer treatment monitoring
Michael van den Heuvel Clinical needs for useful application of tumor markers
Mirza Muhammad Faran Ashraf DNA Nanotechnology for Modulating the Growth and Development of Neurons
Mlinarič Raščan Irena Molecular signatures of venetoclay chronic lymphocytic leukaemia resitence
Muley Thomas Use of tumor marker classificators for post-surgery stratification of patients with early lung cancer
Nicolini Andrea A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone
Oehr Peter A new diagnostic approach for a more realistic tumor marker follow up during therapy
Oehr Peter New established types of ROC-curves and their clinical impact
Podgornik Helena Diagnostic algorithms ensure recognition of Ph-like acute lymphoblastic leukemia molecular markers
Reijnen Casper Integrating biomarkers into ENDORISK prediction model
Ritter Christoph Translational Platform for Anticancer Treatment Strategies
Romano Andrea ENITEC Presentation
Schröder Lea Immunogenic cell death markers in ovarian cancer
Schroeder Christoph Affinity proteomics for the discovery of novel biomarkers and therapeutic targets
Sever Matjaž Clinical implication of CART therapy
Smrkolj Tomaž Biomarkers in urology
Strojnik Andrej Germline genetic testing for cancer treatment in prostate and pancreatic cancer patients
Škerl Petra Methylation status of mismatch repair genes in endometrial and colorectal cancer
Škof Erik Clinical importance of BRCA mutation in ovarian cancer
Šmid Lojze Chromogranin in the diagnostic and therapy of neuroendocrine tumors
Tokarz Janina Metabolomics for deep phenotyping in frequent human diseases
Topolčan Ondrej Significance tumour biomarkers for tumour aggressiveness
Treves Abraham Gut microbiome and fecal transplantation in Cancer treatment
Turnšek Nina Oncogenic driver ALK fusion in NSCLC with case report
Uhlig Carsten Artificial intelligence approaches for tumor marker evaluations
Unk Mojca (R)Evolution of non-small cell lung cancer systemic treatment
van Rossum Huub Continued need for harmonization of tumor marker assays
van Rossum Huub Laboratory needs for reliable application of tumor markers
Viehbaum L Inter-assay comparison of tumor markers in an EQA setting
Wojtaewicz Nathalie Longitudinal variation of tumor markers assays in an EQA setting
Wolf Dominik Risk prediction for GvHD in patients with AML after stem cell transplantation
Zadnik Vesna Public health interventions for reducing cancer burden and improving cancer care: national clinical registries and organised screening programmes